|PUBLICATIONS (Ranked by impact factor of the journal)|
Restoration of PPP2CA Expression Reverses Epithelial-to-Mesenchymal Transition and Suppresses Prostate Tumor Growth and Metastasis in an Orthotopic Mouse Model
Effect on prostate cancer phenotype was studied in vitro and in orthotopic mouse model, and immunohistochemical/histological analyses performed to assess proliferation/apoptosis and confirm metastatic lesions. [Br J Cancer]
Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon Drug Induced DNA Damage under Hypoxia
Researchers showed that prostate cancer cells with mutant p53 were resistant to the poly(ADP-ribose) polymerase inhibitor, veliparib and the DNA-damaging topoisomerase I inhibitor Camptothecin-11 or SN38 under hypoxia. [Mol Pharmacol]
MicroRNA-494-3p Targets CXCR4 to Suppress the Proliferation, Invasion, and Migration of Prostate Cancer
The biological effect of miR-494-3p on prostate cancer cells proliferation, apoptosis, migration, and invasion was measured by MTT, TUNEL, flow cytometry, migration, and invasion assays. [Prostate]
Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer
Scientists determined the efficacy somatostatin analogue octreotide combined with a low dose of docetaxel using castration resistant prostate cancer cells and to investigate the involved molecular mechanisms in vitro. [PLoS One]
NMR-Based Evaluation of the Metabolic Profile and Response to Dichloroacetate of Human Prostate Cancer Cells
Researchers evaluated the metabolic profile of human prostate cancer cells that have different metastatic potential and to determine their response to dichloroacetate using NMR technology. [NMR Biomed]
Comparative Effects of Soy Phytoestrogens and 17ß-Estradiol on DNA Methylation of a Panel of 24 Genes in Prostate Cancer Cell Lines
Scientists investigated the effects of soy phytoestrogens and the natural estrogen 17ß-estradiol to determine whether one of the estrogen receptors is mobilized for the action of these compounds on DNA methylation. [Nutr Cancer]
Sulforaphane and TRAIL Induce a Synergistic Elimination of Advanced Prostate Cancer Stem-Like Cells
The established androgen-independent prostate cancer cell lines DU145 and PC3, with enriched cancer stem cells (CSC) features, and primary patient-derived prostate CSCs were treated with sulforaphane and recombinant soluble TRAIL. Scientists largely found a stronger effect of sulforaphane on CSC properties compared to TRAIL, though the agents acted synergistically when applied in combination. [Int J Oncol]
Download Full Article
Thrombomodulin Mediates the Migratory Ability of Hormone-Independent Prostate Cancer Cells through the Regulation of Epithelial-to-Mesenchymal Transition Biomarkers
Higher levels of thrombomodulin (TM) transcription and translation were found in DU-145 cells and were negatively correlated with the low migratory ability of DU-145 cells. After silencing TM expression in DU-145 cells, cell growth decreased, but cell adhesion and migration dramatically increased. [Tumor Biol]
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
This Phase II trial randomized chemotherapy-naïve men with progressing castration-resistant prostate cancer to receive figitumumab every three weeks with docetaxel/prednisone or docetaxel/prednisone alone. [Clin Cancer Res]
Androgen Dynamics and Serum PSA in Patients Treated with Abiraterone Acetate
Researchers analyzed the potential of abiraterone acetate to reduce androgen levels below lower limits of quantification and explored the association with changes in PSA decline in metastatic castration-resistant prostate cancer patients. [Prostate Cancer Prostatic Dis]
Clinical Pharmacology of an Atrasentan and Docetaxel Regimen in Men with Hormone-Refractory Prostate Cancer
Investigators evaluated potential pharmacokinetic interactions between docetaxel and atrasentan as part of a Phase I/II clinical trial. [Cancer Chemother Pharmacol]
TGF-ß Cascade Regulation by PPP1 and Its Interactors – Impact on Prostate Cancer Development and Therapy|
The authors discuss the role of phosphoprotein phosphatase 1 (PPP1) in the regulation of several transforming growth factor beta (TGF-ß) signaling members and how the subversion of this pathway is related to prostate cancer development. Furthermore, current challenges on the protein phosphatases field as new targets to cancer therapy are addressed. [J Cell Mol Med]
Biomarkers in Prostate Cancer: What’s New?
The authors provide an overview of the current state of biomarkers for prostate cancer, with a focus on biomarkers approved by the US Food and Drug Administration as well as biomarkers available from Clinical Laboratory Improvement Amendment-certified clinical laboratories within the last 1-2 years. [Curr Opin Oncol]
Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.